Hemolytic-uremic syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 7: Line 7:
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence of HUS is approximately 6 per 100,000 younger than 5 years old.<ref name="pmid27723152">{{cite journal |vauthors=Karpman D, Loos S, Tati R, Arvidsson I |title=Haemolytic uraemic syndrome |journal=J. Intern. Med. |volume=281 |issue=2 |pages=123–148 |date=February 2017 |pmid=27723152 |doi=10.1111/joim.12546 |url=}}</ref>
*In children less than 5 years of age, the incidence of HUS is approximately 6 per 100,000.<ref name="pmid27723152">{{cite journal |vauthors=Karpman D, Loos S, Tati R, Arvidsson I |title=Haemolytic uraemic syndrome |journal=J. Intern. Med. |volume=281 |issue=2 |pages=123–148 |date=February 2017 |pmid=27723152 |doi=10.1111/joim.12546 |url=}}</ref>
*In 2016, the incidence of HUS was estimated to be 2 cases per 100,000 individuals worldwide.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref>
*In 2016, the incidence of HUS was estimated to be 2 cases per 100,000 individuals, worldwide.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref>


===Prevalence.===
===Mortality rate===
*The incidence of HUS is approximately 6 per 100,000 younger than 5 years old.<ref name="pmid27723152" />
*In 2017, the mortality of hemolytic uremic syndrome (HUS) is estimated to approximately 10% .<ref>{{Cite journal
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
 
===Case-fatality rate/Mortality rate===
*In 2017, the incidence of hemolytic uremic syndrome (HUS) is approximately 10% .<ref>{{Cite journal
| author = [[Gregory Hall]], [[Shinichiro Kurosawa]] & [[Deborah J. Stearns-Kurosawa]]
| title = Shiga Toxin Therapeutics: Beyond Neutralization
| journal = [[Toxins]]
| volume = 9
| issue = 9
| year = 2017
| month = September
| doi = 10.3390/toxins9090291
| pmid = 28925976
}}</ref>
 
* The case-fatality mortality rate of HUS is approximately 25%.<ref>{{Cite journal
  | author = [[Gregory Hall]], [[Shinichiro Kurosawa]] & [[Deborah J. Stearns-Kurosawa]]
  | author = [[Gregory Hall]], [[Shinichiro Kurosawa]] & [[Deborah J. Stearns-Kurosawa]]
  | title = Shiga Toxin Therapeutics: Beyond Neutralization
  | title = Shiga Toxin Therapeutics: Beyond Neutralization
Line 44: Line 28:


*HUS commonly affects individuals younger 5 older than [number of years] years of age.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref>
*HUS commonly affects individuals younger 5 older than [number of years] years of age.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref>
*[Chronic isease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].
===Race===
===Race===
*HUS usually affects individuals of the white(82%) race<ref name=":0" />.  
*HUS usually affects individuals of the White race (82%).<ref name=":0" />   
===Gender===
===Gender===
*HUS affects woman(59%) more than man(41%) .<ref name=":0">{{Cite journal
*HUS affects female more than male. Approximately 59% of affected individuals are female.<ref name=":0">{{Cite journal
  | author = [[Deirdra R. Terrell]], [[Sara K. Vesely]], [[Johanna A. Kremer Hovinga]], [[Bernhard Lammle]] & [[James N. George]]
  | author = [[Deirdra R. Terrell]], [[Sara K. Vesely]], [[Johanna A. Kremer Hovinga]], [[Bernhard Lammle]] & [[James N. George]]
  | title = Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes
  | title = Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes
Line 63: Line 43:
  | pmid = 20799358
  | pmid = 20799358
}}</ref>
}}</ref>
   
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
===Region===
===Region===
*The majority of [disease name] cases are reported in [geographical region].
*The majority of [disease name] cases are reported in [geographical region].


*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
===Developed Countries===
===Developing Countries===


==References==
==References==

Revision as of 14:25, 30 July 2018

Hemolytic-uremic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic-uremic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic-uremic syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic-uremic syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic-uremic syndrome epidemiology and demographics

CDC on Hemolytic-uremic syndrome epidemiology and demographics

Hemolytic-uremic syndrome epidemiology and demographics in the news

Blogs on Hemolytic-uremic syndrome epidemiology and demographics

Directions to Hospitals Treating Hemolytic-uremic syndrome

Risk calculators and risk factors for Hemolytic-uremic syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • In children less than 5 years of age, the incidence of HUS is approximately 6 per 100,000.[1]
  • In 2016, the incidence of HUS was estimated to be 2 cases per 100,000 individuals, worldwide.[2]

Mortality rate

  • In 2017, the mortality of hemolytic uremic syndrome (HUS) is estimated to approximately 10% .[3]

Age

  • Patients of all age groups may develop hemolytic uremic syndrome (HUS).
  • The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.[2]
  • HUS commonly affects individuals younger 5 older than [number of years] years of age.[2]

Race

  • HUS usually affects individuals of the White race (82%).[4]

Gender

  • HUS affects female more than male. Approximately 59% of affected individuals are female.[4]

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

References

  1. ↑ Karpman D, Loos S, Tati R, Arvidsson I (February 2017). "Haemolytic uraemic syndrome". J. Intern. Med. 281 (2): 123–148. doi:10.1111/joim.12546. PMID 27723152.
  2. ↑ 2.0 2.1 2.2 Karpman, Diana; Loos, Sebastian; Tati, Ramesh; Arvidsson, Ida (2017). "Haemolytic uraemic syndrome". Journal of Internal Medicine. 281 (2): 123–148. doi:10.1111/joim.12546. ISSN 0954-6820.
  3. ↑ Gregory Hall, Shinichiro Kurosawa & Deborah J. Stearns-Kurosawa (2017). "Shiga Toxin Therapeutics: Beyond Neutralization". Toxins. 9 (9). doi:10.3390/toxins9090291. PMID 28925976. Unknown parameter |month= ignored (help)
  4. ↑ 4.0 4.1 Deirdra R. Terrell, Sara K. Vesely, Johanna A. Kremer Hovinga, Bernhard Lammle & James N. George (2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". American journal of hematology. 85 (11): 844–847. doi:10.1002/ajh.21833. PMID 20799358. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Hemolytic-uremic_syndrome_epidemiology_and_demographics&oldid=1486291"